Tumor Biology

, Volume 37, Issue 7, pp 9285–9288 | Cite as

Cyfip1 is downregulated in acute lymphoblastic leukemia and may be a potential biomarker in acute lymphoblastic leukemia

Original Article

Abstract

The aim of the present study was to analyze the expression of Cyfip1 in acute lymphoblastic leukemia (ALL) and its correlations with clinical pathologic features. A total of 86 ALL samples and 32 normal peripheral blood lymphocyte (PBL) samples were enrolled in our study. mRNA expression of the Cyfip1 was assessed by real-time fluorescent relatively quantitative PCR, and Cyfip1 protein expression was evaluated by Western blot analysis. As a result, both mRNA and protein expression levels of Cyfip1 were significantly lower in ALL patients than those in the control samples (P = 0.025 and 0.000, respectively). Moreover, both mRNA and protein expression of both had an inverse relation with lymph node metastasis (P = 0.015 and 0.007, respectively), In conclusion, detecting mRNA and protein expression of Cyfip1 could provide clinically significant information relevant to diagnosis, progression, and treatment modalities for ALL, and Cyfip1 may serve as a potential biomarker for diagnosis and prognosis in ALL.

Keywords

Cyfip1 Acute lymphoblastic leukemia Diagnosis Prognosis 

Notes

Compliance with ethical standards

Written consent was derived from patients, and protocol was also approved by ethics committee of the First Affiliated Hospital of Guangxi Medical University.

References

  1. 1.
    Iughetti L, Bruzzi P, Predieri B, Paolucci P. Obesity in patients with acute lymphoblastic leukemia in childhood. Ital J Pediatr. 2012;38:4.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535–48.CrossRefPubMedGoogle Scholar
  3. 3.
    Dalmasso P, Pastore G, Zuccolo L, Maule MM, Pearce N, Merletti F, et al. Temporal trends in the incidence of childhood leukemia, lymphomas and solid tumors in north-west italy, 1967–2001. A report of the Childhood Cancer Registry of Piedmont. Haematologica. 2005;90:1197–204.PubMedGoogle Scholar
  4. 4.
    Chen X, Zhang H, Li P, Yang Z, Qin L, Mo W. Gene expression of WWOX, FHIT and P73 in acute lymphoblastic leukemia. Oncol Lett. 2013;6:963–9.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Chen X, Li P, Yang Z, Mo WN. Expression of fragile histidine triad (FHIT) and ww-domain oxidoreductase gene (WWOX) in nasopharyngeal carcinoma. Asian Pac J Cancer Prev : APJCP. 2013;14:165–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Silva JM, Ezhkova E, Silva J, Heart S, Castillo M, Campos Y, et al. Cyfip1 is a putative invasion suppressor in epithelial cancers. Cell. 2009;137:1047–61.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ishii H, Vecchione A, Furukawa Y, Sutheesophon K, Han SY, Druck T, et al. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res : MCR. 2003;1:940–7.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of Clinical LaboratoryFirst Affiliated Hospital of Soochow UniversitySuzhouPeople’s Republic of China
  2. 2.Department of Clinical LaboratoryFirst Affiliated Hospital of Guangxi Medical UniversityNanningPeople’s Republic of China

Personalised recommendations